Nitrosamine Risk in the Dossier: Where It Sits in Module 3 and What Triggers a Variation

Nitrosamine risk management is no longer a standalone project; it is part of the quality dossier, and any change to the process, packaging or supplier may reopen the assessment.

The three-step framework

Following the Article 5(3) referral on sartans and later work, EU authorities asked marketing authorisation holders to review all chemical medicines for nitrosamine risk. The process is described in the EMA Questions and Answers document for marketing authorisation holders and applicants, which has been updated several times. It has three steps.

  • Risk evaluation of the active substance and finished product.
  • Confirmatory testing where a risk is identified.
  • Submission of changes through the appropriate variation if mitigation is needed.

Where the evidence lives

For a new application, the risk assessment is expected to be available for the active substance and the finished product, and the outcome is reflected in the quality sections. Relevant points include the synthetic route and reagents, solvents and their recovery, the presence of nitrosating agents and secondary or tertiary amines, excipients, water, packaging and the manufacturing process itself.

Specifications may need a control for a specific nitrosamine, with limits derived from the acceptable intake. The EMA has also published a Carcinogenic Potency Categorisation Approach that can be used for nitrosamine drug substance-related impurities where compound-specific data are lacking. Applicants should check the current Q&A for limits and expectations rather than relying on figures quoted elsewhere.

Changes that reopen the assessment

  • Change of active substance supplier or synthetic route.
  • New or changed solvents, reagents or recovery steps.
  • Formulation changes, including excipients that may contain nitrite.
  • Packaging changes, for example materials containing nitrocellulose in printed foils.
  • Changes of manufacturing site or process conditions.

These should trigger a documented review as part of change control, not only the variation itself.

Practical advice

Keep the risk assessment as a living document that is linked to the quality system. Obtain supplier statements early, because the active substance manufacturer often holds the key information. Where the supplier relies on a master file or certificate, check that the nitrosamine information is up to date there too.

Record decisions even when the conclusion is that no risk exists, since both inspectors and assessors may ask for the reasoning.

Questions to ask before filing

Has a documented risk assessment been completed for every active substance and finished product, and is it signed and dated? Do supplier statements cover every site and route in the dossier? Is there a defined trigger list in change control that sends relevant changes back to the assessment? Do the quality sections state the conclusion clearly and refer to supporting documents that can be produced on request?

How PQRA helps

PQRA supports risk assessments across the supply chain, checks how nitrosamine conclusions are reflected in Module 3, and prepares the variations and responses that follow a confirmed finding.

Talk to us about your dossier: Contact PQRA

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *